Table 1.

Key LC-MS/MS parameters for multiple reaction monitoring (MRM) and enhanced product ion (EPI) acquisition of the 18 target compounds.

Analyte	Retention time (min)	MRM transitions (m/z)	Declustering potential (V)	Collision energy (V)	Collision exit potential (V)	MS/MS fragments (m/z)
Gemcitabine (GCA)	4.71	264/112	60	23	10	264.1, 246.0, 198.0, 194.9, 151.0, 112.1
Dacarbazine (DACA)	5.80	183/166	60	23	10	183.1, 166.0, 138.1, 123.0
Fludarabine (FLD)	5.87	366/154	50	22	10	366.0, 154.1, 134.0
Methotrexate (MTX)	6.57	455/308	60	30	10	455.2, 326.0, 308.2, 175.1, 134.0
Topotecan (TOP)	6.71	422/377	60	32	10	422.2, 377.0, 349.1, 333.2, 320.0, 305.2
Mitomycin (MIT)	6.95	335/242	60	19	10	335.2, 274.1, 242.2, 227.0, 214.1, 199.2
Pemetrexed (PTR)	7.05	428/281	60	28	10	428.3, 382.1, 299.1, 281.1, 253.3, 163.2, 119.0
Irinotecan (IRI)	7.67	587/502	60	43	10	587.3, 543.4, 502.3, 458.3, 414.4, 331.2, 303.1, 195.2, 167.0, 124.1
Vincristine (VCR)	7.92	413/353	60	23	10	413.3, 392.2, 383.0, 362.3, 353.3
Doxorubicin (DOXO)	8.01	544/397	60	19	10	544.0, 397.2, 379.1, 361.0, 346.0, 333.0, 321.0
Vinblastine (VBL)	8.18	406/271	100	25	10	406.3, 397.1, 376.1, 346.4, 271.9
Vinorelbine (VIN)	8.66	390/122	60	19	10	658.2, 626.2, 598.3, 566.0, 360.5, 122.0
Bendamustine (BEN)	8.81	358/304	60	40	10	358.1, 340.1, 322.2, 304.2, 242.2, 228.4
Ifosfamide (IF)	9.03	261/154	60	32	10	261.0, 233.0, 182.2, 154.0, 120.1
Cyclophosphamide (CP)	9.17	261/140	60	35	10	261.1, 233.2, 142.0, 140.0, 106.2, 104.0
Etoposide (ETOP)	9.36	589/229	60	23	10	589.3, 383.3, 299.2, 247.1, 229.1, 217.1, 199.1, 185.2
Docetaxel (DOCE)	12.8	808/226	20	20	10	808.4, 591.2, 531.2, 527.2, 509.2, 345.3, 327.2, 309.1, 281.1, 226.2, 181.9
Paclitaxel (TAX)	12.9	854/286	60	20	10	854.4, 569.2, 509.2, 447.2, 286.3
Topotecan-d6 (IS)	6.70	428/377	100	25	10	-
Irinotecan-d10 (IS)	7.65	597/133	100	47	10	-
Bendamustine-d6 (IS)	8.79	364.1/232	100	50	10	-
Docetaxel-d9 (IS)	12.8	839a/549	60	34	10	-

^aSodium adduct was monitored.